CAMP4 Therapeutics announced a new research collaboration with BioMarin Pharmaceutical Inc. aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA sequences, which are key elements controlling gene expression. Under the terms of the agreement, BioMarin has the right to select two targets identified by CAMP4’s RAP Platform to advance into clinical development.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical Projects Strong Growth Through 2034
- Ascendis Pharma price target raised to $191 from $175 at BofA
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 9/19/2024, According to Top Analysts
- BioMarin near-term impact from Ascendis data overblown, says Citi